Captaru
  • Grants
  • Volunteers
  • Community
  • Pricing
  • About
    Who We AreOur PartnersJobs
  • Transparency
  • Blog
  • Contact
Captaru Logo

Starting from what we can do and think, our strength is bringing our own and third-party social projects to life.

proyectos@captaru.org
CAPTARU
  • ABOUT US
  • PROJECTS
  • Grant management
  • NGO platform
  • EU funding
  • TRANSPARENCY
  • CONTACT
FOLLOW US
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
Preferred source on Google
JOIN OUR NEWSLETTER AND NEVER MISS AN OPPORTUNITY
Legal NoticeDisclaimerCookie PolicyPrivacy StatementSubscription Terms

Fundación Plaza de Castilla, CIF G84070945, registered at Serrano Anguita 13, 28004 Madrid.

CAPTARU IS A PROJECT DEVELOPED WITH PASSION BY FUNDACIÓN PLAZA DE CASTILLA © 2026 ALL RIGHTS RESERVED

Back to list
Start a proposal with Captaru
🇺🇸GRANTS_GOVOPENGRANT385 days left

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

🏛 GRANTS_GOV · 📍 US

Total budget

Not specified

OPENING

Nov 5, 2024

CLOSING

Oct 25, 2027

Category

Education / Health

Description

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

Official source

View official source ↗

Eligible beneficiaries

  • Small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Private institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Special district governments
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • City or township governments
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • State governments
  • For profit organizations other than small businesses
  • Public housing authorities/Indian housing authorities
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Public and State controlled institutions of higher education

Related calls

  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
  • Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
See all open grants